The Impacts of Suppressing Cellular Innate Immune Responses on AAV Yields During Production

Poster highlights a study by Virica Biotech and the Center for Breakthrough Medicines showing that suppressing innate immune responses with Viral Sensitizers (VSEs™) significantly improves AAV yield and quality. Screening of eight VSEs identified a VSE compound that increases full particle output across multiple serotypes with minimal impact on cell viability. Downstream analysis confirmed enhanced full capsid recovery, demonstrating the potential of VSEs to overcome innate cellular barriers and improve viral vector manufacturing.